Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.41 |
| ▸ | MMP9 | P14780 | 13/20 | 0.40 |
| ▸ | MMP13 | P45452 | 13/20 | 0.40 |
| ▸ | MMP1 | P03956 | 12/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6408359 | 0.94 | ALDH1A1 (0.41) | CCR5MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6411170 | 0.93 | CCR5 (0.44) | CCR5MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6409151 | 0.93 | CCR5 (0.44) | CCR5MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6408481 | 0.92 | DRD2 (0.41) | CCR5 | |
| Hydrochloric Acid SCHEMBL5256271 | 0.92 | CCR5 (0.43) | CCR5MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6408483 | 0.92 | CCR2 (0.44) | CCR5ALDH1A1 | |
| SCHEMBL6412914 | 0.92 | CCR2 (0.44) | CCR5ALDH1A1 | |
| SCHEMBL6409321 | 0.91 | UTS2R (0.42) | CCR5MMP9MMP13MMP1ADAM17 | |
| SCHEMBL6414389 | 0.90 | CCR5 (0.37) | CCR5ALDH1A1 | |
| SCHEMBL6412239 | 0.90 | CCR5 (0.45) | CCR5MMP9MMP13MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | CCR5 4/4885MMP9 884/4885MMP13 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.